ArticleERJ open research2025
Clinical relevance of microvascular endothelial dysfunction in idiopathic pulmonary fibrosis.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endothelial dysfunction (ED) is involved in the pathophysiology of idiopathic pulmonary fibrosis (IPF). Reactive hyperaemia peripheral arterial tonometry (RH-PAT) is a rapid, reproducible, noninvasive technique for assessing peripheral microvascular endothelial function. Methods: We conducted a prospective study of endothelial function (reactive hyperaemia index (RHI) as measured by RH-PAT) in patients with IPF, in order to explore the association between ED and respiratory symptoms, lung function and the disease prognosis. Adult patients with IPF underwent a baseline assessment of respiratory symptoms (including dyspnoea on the modified Medical Research Council scale), blood gas levels, pulmonary function tests, a 6-min walk test (6MWT) and endothelial function. The same examinations were performed 12, 24 and 36 months after inclusion. Results: 42 patients with IPF (men: 76%) were enrolled. The median (IQR) age was 70 (61-75) years. The median (IQR) forced vital capacity and diffusing capacity of the lung for carbon monoxide ( Conclusion: Finger ED was correlated with respiratory symptoms and functional variables and worsened during the first year of follow-up. Our results suggest that the severity of IPF is associated with ED, although further studies are needed to assess the value of RH-PAT in the management of IPF.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.